Practice guidelines for management of hepatocellular carcinoma 2009
|
|
Korean Liver Cancer Study Group,
(Korean Liver Cancer Study Group)
National Cancer Center, (National Cancer Center) |
| 1 | Korean Statistical Information Services |
| 2 | Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236 DOI ScienceOn |
| 3 | Ishizuka H, Nakayama T, Matsuoka S, Gotoh I, Ogawa M, Suzuki K, et al. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med 1999;38:927-931 DOI ScienceOn |
| 4 | Yoon YJ, Han KH, Kim C, Chon CY, Moon YM, Han CH, et al. Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma. Korean J Hepatol 2002;8:465-471 |
| 5 | Zacherl J, Pokieser P, Wrba F, Scheuba C, Prokesch R, Zacherl M, et al. Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth? Ann Surg 2002;235:528-532 DOI ScienceOn |
| 6 | Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatol Res 2007;37(Suppl 2): S178-S192 DOI |
| 7 | Capussotti L, Muratore A, Massucco P, Ferrero A, Polastri R, Bouzari H. Major liver resections for hepatocellular carcinoma on cirrhosis: early and long-term outcomes. Liver Transpl 2004;10(Suppl 1):S64-S68 DOI ScienceOn |
| 8 | Kim JH, Choi DW, Kim SB. Saftey and long-term outcome following major hepatectomy for hepatocellular carcinoma combined with compensated liver cirrhosis. J Korean Surg Soc 2006;70:444-450 |
| 9 | Torzilli G, Palmisano A, Del Fabbro D, Marconi M, Donadon M, Spinelli A, et al. Contrast-enhanced intraoperative ultrasonography during surgery for hepatocellular carcinoma in liver cirrhosis: is it useful or useless? A prospective cohort study of our experience. Ann Surg Oncol 2007;14:1347-1355 DOI ScienceOn |
| 10 | Zhang K, Kokudo N, Hasegawa K, Arita J, Tang W, Aoki T, et al. Detection of new tumors by intraoperative ultrasonography during repeated hepatic resections for hepatocellular carcinoma. Arch Surg 2007;142:1170-1175 DOI ScienceOn |
| 11 | Hanazaki K, Kajikawa S, Shimozawa N, Matsushita A, Machida T, Shimada K, et al. Perioperative blood transfusion and survival following curative hepatic resection for hepatocellular carcinoma. Hepatogastroenterology 2005;52:524-529 PUBMED ScienceOn |
| 12 | Tsujita E, Taketomi A, Kitagawa D, Itoh S, Harimoto N, Gion T, et al. Selective hepatic vascular exclusion for the hepatic resection of HCC. Hepatogastroenterology 2007;54: 527-530 PUBMED ScienceOn |
| 13 | Kaneko H, Takagi S, Otsuka Y, Tsuchiya M, Tamura A, Katagiri T, et al. Laparoscopic liver resection of hepatocellular carcinoma. Am J Surg 2005;189:190-194 DOI ScienceOn |
| 14 | Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 2004;28: 376-381 DOI ScienceOn |
| 15 | Tralhao JG, Kayal S, Dagher I, Sanhueza M, Vons C, Franco D. Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology 2007;54:1200-1206 PUBMED ScienceOn |
| 16 | Chen HY, Juan CC, Ker CG. Laparoscopic liver surgery for patients with hepatocellular carcinoma. Ann Surg Oncol 2008;15:800-806 DOI ScienceOn |
| 17 | Vibert E, Perniceni T, Levard H, Denet C, Shahri NK, Gayet B. Laparoscopic liver resection. Br J Surg 2006;93: 67-72 DOI ScienceOn |
| 18 | Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005;137:403-410 DOI ScienceOn |
| 19 | Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcomeoriented decision analysis. Hepatology 2000;31:899-906 DOI ScienceOn |
| 20 | Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11:1265-1272 DOI ScienceOn |
| 21 | Gondolesi GE, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein TM, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004;239: 142-149 DOI ScienceOn |
| 22 | Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002;50:123-128 DOI ScienceOn |
| 23 | Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequencyablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900-909 DOI ScienceOn |
| 24 | Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-382 DOI ScienceOn |
| 25 | Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, TakagiT, et al. Simultaneous measurements of serum alphafetoproteinand protein induced by vitamin K absence fordetecting hepatocellular carcinoma. South Tohoku DistrictStudy Group. Am J Gastroenterol 2000;95:1036-1040 PUBMED |
| 26 | Jonas S, Bechstein WO, Steinmuller T, Herrmann M,Radke C, Berg T, et al. Vascular invasion and histopathologicgrading determine outcome after liver transplantationfor hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-1086 DOI ScienceOn |
| 27 | Schwartz M, Roayaie S, Llovet J. How should patientswith hepatocellular carcinoma recurrence after livertransplantation be treated? J Hepatol 2005;43:584-589 DOI ScienceOn |
| 28 | Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, RocheB, Fallot G, et al. Hepatocellular carcinoma is associatedwith an increased risk of hepatitis B virus recurrenceafterliver transplantation. Gastroenterology 2008;134:1890-1899 DOI ScienceOn |
| 29 | Zimmerman MA, Trotter JF, Wachs M, Bak T, CampsenJ, Skibba A, et al. Sirolimus-based immunosuppressionfollowing liver transplantation for hepatocellular carcinoma.Liver Transpl 2008;14:633-638 DOI ScienceOn |
| 30 | Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY,et al. Prevention of hepatitis B recurrence after livingdonor liver transplantation: primary high-dose hepatitis Bimmunoglobulin monotherapy and rescue antiviral therapy.Liver Transpl 2008;14:770-778 DOI ScienceOn |
| 31 | Shiina S, Teratani T, Obi S, Sato S, Tateishi R,Fujishima T, et al. A randomized controlled trial ofradiofrequency ablation with ethanol injection for smallhepatocellular carcinoma. Gastroenterology 2005;129:122-130 DOI ScienceOn |
| 32 | Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, etal. Percutaneous radiofrequency ablation for early-stagehepatocellular carcinoma as a first-line treatment: longtermresults and prognostic factors in a large singleinstitutionseries. Eur Radiol 2007;17:684-692 DOI ScienceOn |
| 33 | Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, ZhangYQ, et al. A prospective randomized trial comparingpercutaneous local ablative therapy and partial hepatectomyfor small hepatocellular carcinoma. Ann Surg 2006;243:321-328 DOI ScienceOn |
| 34 | Daniele B, De Sio I, Izzo F, Capuano G, Andreana A,Mazzanti R, et al. Hepatic resection and percutaneousethanol injection as treatments of small hepatocellularcarcinoma: a Cancer of the Liver Italian Program (CLIP08) retrospective case-control study. J Clin Gastroenterol 2003;36:63-67 DOI ScienceOn |
| 35 | Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005;11:6104-6109 DOI PUBMED |
| 36 | Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, Lee KU, et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002;20:4459-4465 DOI ScienceOn |
| 37 | Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995;165:315-321 DOI PUBMED ScienceOn |
| 38 | Park JH, Chung JW, Lee SK, Han JK, Lee HS, Kim CY, et al. Chemoembolization of hepatocellular carcinoma: long-term survival and prognostic factors. J Korean Radiol Soc 1996;35:315-323 |
| 39 | Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12:2563-2567 DOI ScienceOn |
| 40 | Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81 DOI ScienceOn |
| 41 | Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009;49:1185-1193 DOI ScienceOn |
| 42 | Seong J, Lee IJ, Shim SJ, Lim do H, Kim TH, Kim JH, et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 2009;29:147-152 DOI PUBMED ScienceOn |
| 43 | Guo WJ, Yu EX. The long-term efficacy of combined chemoembolization and local irradiation in the treatment of patients with large hepatocellular carcinoma. Hepatogastroenterology 2003;50:500-503 PUBMED |
| 44 | Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003;55:329-336 DOI PUBMED ScienceOn |
| 45 | Kim TH, Kim DY, Park JW, Kim SH, Choi JI, Kim HB, et al. Dose-volumetric parameters predicting radiationinduced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:225-231 DOI PUBMED ScienceOn |
| 46 | Cheng SH, Lin YM, Chuang VP, Yang PS, Cheng JC, Huang AT, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:1025-1033 DOI ScienceOn |
| 47 | Yamashita H, Nakagawa K, Shiraishi K, Tago M, Igaki H, Nakamura N, etal. Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol 2007;22: 523-527 DOI ScienceOn |
| 48 | Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005;25:261-265 DOI PUBMED ScienceOn |
| 49 | Taki Y, Yamaoka Y, Takayasu T, Ino K, Shimahara Y, Mori K, et al. Bone metastases of hepatocellular carcinoma after liver resection. J Surg Oncol 1992;50: 12-18 DOI ScienceOn |
| 50 | Murakami R, Baba Y, Furusawa M, Yokoyama T, Nishimura R, Uozumi H, et al. Short communication: the value of embolization therapy in painful osseous metastases from hepatocellular carcinomas; comparative study with radiation therapy. Br J Radiol 1996;69:1042-1044 DOI ScienceOn |
| 51 | Choi HJ, Cho BC, Sohn JH, Shin SJ, Kim SH, Kim JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol 2009;91:307-313 DOI ScienceOn |
| 52 | Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 2005;11:3799-3805 DOI ScienceOn |
| 53 | Fong Y KN, Lawrence T. Cancer of the liver and biliary tree. In: De Vita VT, Hellman S, Rosenberg S, eds. Cancer: Principles and Practices of Oncology 2001;1: 1162-1204 |
| 54 | Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002;35(Suppl 2):S109-S114 DOI ScienceOn |
| 55 | Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390 DOI ScienceOn |
| 56 | Shim JH, Park JW, Choi JI, Park BJ, Kim CM. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009;135: 617-625 DOI ScienceOn |
| 57 | Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528 DOI PUBMED ScienceOn |
| 58 | Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136: 699-712 DOI ScienceOn |
| 59 | Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006;4:1076-1081 DOI ScienceOn |
| 60 | Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemolipiodolization. Hepatology 2006;43:233-240 DOI ScienceOn |
| 61 | Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-1554 DOI ScienceOn |
| 62 | Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response totreatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 DOI ScienceOn |
| 63 | Walzer N, Kulik LM. Hepatocellular carcinoma: latest developments. Curr Opin Gastroenterol 2008;24:312-319 DOI ScienceOn |
| 64 | Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008;207:20-29 DOI ScienceOn |
| 65 | Hori T, Nagata K, Hasuike S, Onaga M, Motoda M, Moriuchi A, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol 2003; 38:977-981 DOI ScienceOn |
| 66 | Kim YS, Rhim H, Cho OK, Koh BH, Kim Y. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006;59:432-441 DOI ScienceOn |
| 67 | Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 2002;132:605-611 DOI ScienceOn |
| 68 | Ghobrial RM, Freise CE, Trotter JF, Tong L, Ojo AO, Fair JH, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008:135:468-476 DOI PUBMED ScienceOn |
| 69 | Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007;72(Suppl 1):52-57 ScienceOn |
| 70 | Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis 2007;25:329-333 DOI ScienceOn |
| 71 | Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005;25:1189-1196 DOI PUBMED ScienceOn |
| 72 | Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, et al. Prospective trial of combined transcatheter arterial chemoembolization and three- dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-119 DOI PUBMED ScienceOn |
| 73 | Yoon SM, Kim JH, Choi EK, Ahn SD, Lee SW, Yi BY. Radioresponse of hepatocellular carcinoma: treatment of lymph node metastasis. Cancer Res Treat 2004;36:79-84 DOI ScienceOn |
| 74 | Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539 |
| 75 | Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, et al. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984;86:1404-1409 PUBMED ScienceOn |
| 76 | Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, et al. Sensitivity and specificity of desgamma- carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101:2038-2043 DOI ScienceOn |
| 77 | Makuuchi M, Kokudo N, Arii S, Futagawa S,Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51 DOI ScienceOn |
| 78 | Suh KS. Systematic hepatectomy for small hepatocellular carcinoma in Korea. J Hepatobiliary Pancreat Surg 2005;12: 365-370 DOI PUBMED ScienceOn |
| 79 | Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009:CD001199 |
| 80 | Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43 DOI ScienceOn |
| 81 | Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006;106:1653-1663 DOI ScienceOn |
| 82 | Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005;61:432-443 DOI PUBMED ScienceOn |
| 83 | Lohe F, Angele MK, Gerbes AL, Lohrs U, Jauch KW, Schauer RJ. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005;31:994-999 DOI ScienceOn |
| 84 | Huang JF, Wang LY, Lin ZY, Chen SC, Hsieh MY, Chuang WL, et al. Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17:190-195 DOI ScienceOn |
| 85 | Koneru B, Teperman LW, Manzarbeitia C, Facciuto M, Cho K, Reich D, et al. A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma. Ann Surg 2005;241:622-628 DOI ScienceOn |
| 86 | Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA,Blitz M, Ma MM, et al. Sirolimus-based immunosuppressionfor liver transplantation in the presence ofextended criteria for hepatocellular carcinoma. LiverTranspl 2004;10:1301-1311 DOI ScienceOn |
| 87 | Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J.Tumor size determines the efficacy of percutaneousethanol injection for the treatment of small hepatocellularcarcinoma. Hepatology 1992;16:353-357 DOI PUBMED |
| 88 | Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008;247:260-266 DOI ScienceOn |
| 89 | Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005;15:279- 283 DOI ScienceOn |
| 90 | Shim JH, Park JW, Nam BH, Lee WJ, Kim CM. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:459-467 DOI ScienceOn |
| 91 | Lee KW. 1000 Cases of surgical resection for hepatocellular carcinoma. Kor J HBP Surgery postgraduate course 1998 |
| 92 | Park JW. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 2004;10:88-98 PUBMED |
| 93 | Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422 PUBMED ScienceOn |
| 94 | Ng KK, Vanthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, et al. Is hepatic resection for large or multinodular hepatocelluar carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005;12:364-373 DOI ScienceOn |
| 95 | Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699 DOI ScienceOn |
| 96 | Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001;233:652-659 DOI ScienceOn |
| 97 | Rhim H, Yoon KH, Lee JM, Cho Y, Cho JS, Kim SH, etal. Major complications after radio-frequency thermalablation of hepatic tumors: spectrum of imaging findings.Radiographics 2003;23:123-134 DOI ScienceOn |
| 98 | Matsui O, Kadoya M, Yoshikawa J, Gabata T, TakashimaT, Demachi H. Subsegmental transcatheter arterialembolization for small hepatocellular carcinomas: localtherapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 1994;33(Suppl 1):S84-S88 DOI |
| 99 | Ganne-Carrie N, Trinchet JC. Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004;16:275-281 PUBMED ScienceOn |
| 100 | Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008;143:182-188 DOI ScienceOn |
| 101 | Melloul E, Dondero F, Paugam-Burtz C, Bouadma L, Arnulf B, Belghiti J. Living liver donor death related to complications of myeloma. Liver Transpl 2009;15:326-329 DOI ScienceOn |
| 102 | Marsh JW, Casavilla A, Iwatsuki S, Dvorchik I, Subotin M, Balan V, et al. Predicting the risk of tumor recurrence following transplantation for hepatocellular carcinoma. Hepatology 1997;26:1689-1691 DOI PUBMED ScienceOn |
| 103 | Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307 DOI ScienceOn |
| 104 | Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999;94: 3028-3033 PUBMED |
| 105 | Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108 |
| 106 | Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698-703 PUBMED ScienceOn |
| 107 | Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-1660 DOI ScienceOn |
| 108 | Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K,Kojiro M, et al. Results of surgical and nonsurgicaltreatment for small-sized hepatocellular carcinomas: aretrospective and nationwide survey in Japan. The LiverCancer Study Group of Japan. Hepatology 2000;32:1224-1229 DOI ScienceOn |
| 109 | Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T,et al. Prospective cohort study of transarterial chemoembolizationfor unresectable hepatocellular carcinomain 8510 patients. Gastroenterology 2006;131: 461-469 DOI PUBMED ScienceOn |
| 110 | Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009;10:25-34 DOI ScienceOn |
| 111 | Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214 DOI ScienceOn |
| 112 | Hwang S, Lee SG, Lee YJ, Sung KB, Park KM, Kim KH, et al. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl 2006;12:920-927 DOI ScienceOn |
| 113 | Tanaka H, Hirohashi K, Kubo S, Shuto T, Higaki I, Kinoshita H. Preoperative portal vein embolization improves prognosis after right hepatectomy for hepatocellular carcinoma in patients with impaired hepatic function. Br J Surg 2000;87:879-882 DOI ScienceOn |
| 114 | Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-539 DOI ScienceOn |
| 115 | Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557-563 DOI ScienceOn |
| 116 | Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, AyusoC, et al. Initial response to percutaneous ablation predictssurvival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-1360 DOI ScienceOn |
| 117 | Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104 DOI ScienceOn |
| 118 | Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K,Ozaki K, et al. Ultraselective transcatheter arterialchemoembolization with a 2-f tip microcatheter for smallhepatocellular carcinomas: relationship between localtumor recurrence and visualization of the portal vein withiodized oil. J Vasc Interv Radiol 2007;18:365-376 DOI ScienceOn |
| 119 | Llovet JM, Bruix J. Systematic review of randomizedtrials for unresectable hepatocellular carcinoma: Chemoembolizationimproves survival. Hepatology 2003;37:429-442 DOI ScienceOn |
| 120 | Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58 DOI ScienceOn |
| 121 | Kim KA, Lee JS, Jung ES, Kim JY, Bae WK, Kim NH, et al. Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development. Korean J Gastroenterol 2006;48:321-326 PUBMED |
| 122 | Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematicreview of randomized trials for hepatocellular carcinomatreated with percutaneous ablation therapies. Hepatology 2009;49:453-459 DOI ScienceOn |
| 123 | Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232 DOI ScienceOn |
| 124 | Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247 DOI ScienceOn |
| 125 | Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-744 DOI ScienceOn |
| 126 | Kudo M, Okanoue T; Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(Suppl 1): 2-15 PUBMED |
| 127 | Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005;25:133-142 DOI ScienceOn |
| 128 | Hai L, Yong-Hong P, Yong F, Ren-Feng L. One-stage liver resection for spontaneous rupture of hepatocellular carcinoma. World J Surg 2005;29:1316-1318 DOI ScienceOn |
| 129 | Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003;238: 703-710 DOI ScienceOn |
| 130 | Compagnon P, Grandadam S, Lorho R, Turlin B, CamusC, Jianrong Y, et al. Liver transplantation for hepatocellularcarcinoma without preoperative tumor biopsy.Transplantation 2008;86:1068-1076 DOI ScienceOn |
| 131 | Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW,et al. Comparing the outcomes of radiofrequency ablationand surgery in patients with a single small hepatocellularcarcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005;39:247-252 DOI ScienceOn |
| 132 | Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A,Memeo V. Single hepatocellular carcinoma ranging from3 to 5 cm: radiofrequency ablation or resection? HPB(Oxford) 2007;9:429-434 DOI PUBMED ScienceOn |
| 133 | Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ,Pearce NW, Nicoli N. Surgical resection versus radiofrequencyablation in the treatment of small unifocalhepatocellular carcinoma. J Gastrointest Surg 2008;12:1521-1526 DOI ScienceOn |
| 134 | Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-1681 PUBMED ScienceOn |
| 135 | Johnson PJ. Is there a role for systemic therapy in hepatocellular carcinoma, and if so, can we assess response? Educational book, American Society of Clinical Oncology 2002 |
| 136 | Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-709 DOI ScienceOn |
| 137 | Yao FY, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S, et al. Excellent outcome following downstaging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-827 DOI ScienceOn |
| 138 | Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P’eng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995;82:122-126 DOI ScienceOn |
| 139 | Wakai T, Shirai Y, Sakata J, Kaneko K, Cruz PV, Akazawa K, et al. Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol 2007;14:1356-1365 DOI ScienceOn |
| 140 | Choi GH, Kim DH, Kang CM, Kim KS, Choi JS, Lee WJ, et al. Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma. Ann Surg Oncol 2008;15:618-629 DOI ScienceOn |
| 141 | Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequencyablation improves prognosis compared withethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127:1714-1723 DOI PUBMED ScienceOn |
| 142 | Okada S. Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis 1999;19:323-328 DOI PUBMED ScienceOn |
| 143 | Llovet JM, Real MI, Montana X, Planas R, Coll S, AponteJ, et al. Arterial embolisation or chemoembolisationversus symptomatic treatment in patients with unresectablehepatocellular carcinoma: a randomised controlledtrial. Lancet 2002;359:1734-1739 DOI PUBMED ScienceOn |
| 144 | Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006;29:568-575 DOI ScienceOn |
| 145 | Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16: 1653-1659 DOI PUBMED ScienceOn |
| 146 | De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 2009;9:1158-1168 DOI ScienceOn |
| 147 | Sugawara Y, Tamura S, Makuuchi M. Living donor livertransplantation for hepatocellular carcinoma: Tokyo Universityseries. Dig Dis 2007;25:310-312 DOI ScienceOn |
| 148 | Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J.Hepatic resection for hepatocellular carcinoma. An auditof 343 patients. Ann Surg 1995;221:291-298 |
| 149 | Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drugeluting bead. Clin Gastroenterol Hepatol 2007;5:1100-1108 DOI ScienceOn |
| 150 | Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009;92:184-194 DOI ScienceOn |
| 151 | Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-883 DOI ScienceOn |
| 152 | Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-5423 PUBMED ScienceOn |
| 153 | Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A prospective evaluation of 18F-FDG and 11Cacetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49: 1912-1921 DOI ScienceOn |
| 154 | Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-575 DOI ScienceOn |
| 155 | Lang H, Sotiropoulos GC, Domland M, Fruhauf NR, Paul A, Husing J, et al. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg 2005;92:198-202 DOI ScienceOn |
| 156 | An M, Park JW, Shin JA, Choi JI, Kim TH, Kim SH, et al. The adverse effect of indirectly diagnosed portal hypertension on the complications and prognosis after hepatic resection of hepatocellular carcinoma. Korean J Hepatol 2006;12:553-561 PUBMED |
| 157 | Kim IS, Lim YS, Yoon HK, Sung KB, Jang MK, Choi WB, et al. The effect of preoperative transarterial chemoembolization on the patient's outcome in resectable hepatocellular carcinoma. Korean J Med 2005;69:614-621 |
| 158 | Nakagawa T, Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Matsushita M, et al. Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg 2006;131: 1248-1254 DOI ScienceOn |
| 159 | de Baere T, Risse O, Kuoch V, Dromain C, Sengel C,Smayra T, et al. Adverse events during radiofrequencytreatment of 582 hepatic tumors. AJR Am J Roentgenol 2003;181:695-700 DOI PUBMED ScienceOn |
| 160 | Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-417 DOI PUBMED ScienceOn |
| 161 | Gournay J, Tchuenbou J, Richou C, Masliah C, Lerat F,Dupas B, et al. Percutaneous ethanol injection vs.resection in patients with small single hepatocellularcarcinoma: a retrospective case-control study with costanalysis. Aliment Pharmacol Ther 2002;16:1529-1538 DOI ScienceOn |
| 162 | Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-222 DOI ScienceOn |
| 163 | Yi NJ, Suh KS, Cho JY, Lee HW, Cho EH, Yang SH, et al. Three-quarters of right liver donors experienced postoperative complications. Liver Transpl 2007;13:797-806 DOI ScienceOn |
| 164 | Akabayashi A, Slingsby BT, Fujita M. The first donor death after living-related liver transplantation in Japan. Transplantation 2004;77:634 PUBMED |
| 165 | Guo WJ, Yu EX, Liu LM, Li J, Chen Z, Lin JH, et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003;9:1697-1701 PUBMED ScienceOn |
| 166 | Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-481 DOI ScienceOn |
| 167 | Network NCC. NCCN Clinical Practice Guidelines in Oncology - v.2.2008. Hepatobiliary Cancers |
| 168 | Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005;103:2419-2426 DOI ScienceOn |
| 169 | Park YJ, Lim do H, Paik SW, Koh KC, Lee JH, Choi MS, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol 2006;41:1099-1106 DOI ScienceOn |
| 170 | Nakamura N, Igaki H, Yamashita H, Shiraishi K, Tago M, Sasano N, et al. A retrospective study of radiotherapy for spinal bone metastases from hepatocellular carcinoma (HCC). Jpn J Clin Oncol 2007;37:38-43 DOI ScienceOn |
| 171 | Park JW, Park KW, Cho SH, Park HS, Lee WJ, Lee DH, et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol 2005; 100:2194-2200 DOI ScienceOn |
| 172 | Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994;106:1618-1624 DOI PUBMED ScienceOn |
| 173 | Jain D. Diagnosis of hepatocellular carcinoma: fine needle aspiration cytology or needle core biopsy. J Clin Gastroenterol 2002;35(Suppl 2):S101-S108 DOI ScienceOn |
| 174 | Giardina MG, Matarazzo M, Morante R, Lucariello A, Varriale A, Guardasole V, et al. Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer 1998; 83:2468-2474 DOI ScienceOn |
| 175 | Kim SH, Choi BI, Lee JY, Kim SJ, So YH, Eun HW, et al. Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the milan criteria before liver transplantation. Intervirology 2008;51(Suppl 1):52-60 ScienceOn |
| 176 | Kuo SW, Chang YL, Huang PM, Hsu HH, Chen JS, Lee JM, et al. Prognostic factors for pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 2007;14: 992-997 DOI ScienceOn |
| 177 | Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999;17:324-331 PUBMED ScienceOn |
| 178 | Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma.Lancet 2003;362:1907-1917 DOI ScienceOn |
| 179 | Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A,Rapaccini GL, et al. Percutaneous ethanol injection in thetreatment of hepatocellular carcinoma in cirrhosis. Astudy on 207 patients. Cancer 1992;69:925-929 DOI ScienceOn |
| 180 | Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94: 421-427 DOI ScienceOn |
| 181 | Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003;14:1267-1274 DOI PUBMED ScienceOn |
| 182 | Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-775 DOI ScienceOn |
| 183 | Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, SolbiatiL, Gazelle GS. Small hepatocellular carcinoma: treatmentwith radio-frequency ablation versus ethanol injection.Radiology 1999;210:655-661 DOI PUBMED ScienceOn |
| 184 | Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 2004;127(Suppl 1):S189-S193 DOI |
| 185 | Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005;23:1839-1846 DOI ScienceOn |
| 186 | Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 2003;238:315-321 PUBMED ScienceOn |
| 187 | Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63-70 DOI ScienceOn |
| 188 | Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004;10(Suppl 1):S46-S52 DOI ScienceOn |
| 189 | Sheth H, Javed SS, Hilson AJ, Buscombe JR, Davidson BR. Radioisotope bone scans in the preoperative staging of hepatopancreatobiliary cancer. Br J Surg 2005;92:203-207 DOI ScienceOn |
| 190 | Ellsmere J, Kane R, Grinbaum R, Edwards M, Schneider B, Jones D. Intraoperative ultrasonography during planned liver resections: why are we still performing it? Surg Endosc 2007;21:1280-1283 DOI ScienceOn |
| 191 | Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, KimCY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997;79:2087-2094 DOI ScienceOn |
| 192 | Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004;10:449-455 DOI ScienceOn |
| 193 | Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G,Moretto P, et al. Radiofrequency ablation versus ethanolinjection for early hepatocellular carcinoma: a randomizedcontrolled trial. Scand J Gastroenterol 2008;43:727-735 DOI ScienceOn |
| 194 | Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54 DOI PUBMED ScienceOn |
| 195 | Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007;69:813-819 DOI PUBMED ScienceOn |
| 196 | Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005;61:1143-1150 PUBMED ScienceOn |
| 197 | Dawson LA, McGinn CJ, Lawrence TS. Conformal chemoradiation for primary and metastatic liver malignancies. Semin Surg Oncol 2003;21:249-255 DOI ScienceOn |
| 198 | Kubo S, Nishiguchi S, Hamba H, Hirohashi K, Tanaka H, Shuto T, et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg 2001;233:139-145 DOI ScienceOn |
| 199 | Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207 PUBMED |
| 200 | Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911-918 DOI ScienceOn |
| 201 | Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology 2008;51(Suppl 1):34-41 DOI ScienceOn |
| 202 | Kim MJ, Bae KW, Seo PJ, Jeong IK, Kim JH, Lee BH, et al. Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma: using ROC curve. Korean J Hepatol 2006;12:404-411 PUBMED |
| 203 | Ministry for Health and Welfare, National Cancer Center. Annual report of cancer incidence and survivalin Korea. 2003 |
| 204 | Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-217 DOI ScienceOn |
| 205 | Suh KS, Yi NJ. Liver transplantation for hepatocellular carcinoma. Korean J Hepatol 2006;12:493-506 PUBMED |
| 206 | Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20-S37 |
| 207 | Woo HY, Jang JW, Choi JY,You CR, Jeong SW, Bae SH, et al. Living donor liver transplantation in hepatocellular carcinoma beyond the Milan criteria. Liver Int 2008;28:1120-1128 DOI PUBMED ScienceOn |
| 208 | Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007; 141:598-609 DOI ScienceOn |
| 209 | Schwartz M. Liver transplantation for hepatocellular carcinoma.Gastroenterology 2004;127(Suppl 1):S268-S276 DOI ScienceOn |
| 210 | Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004;99:2369-2375 DOI ScienceOn |
| 211 | KONOS. Annual report. www.konos.go.kr. 2007. |
| 212 | Hwang S, Lee SG, Moon DB, Ahn CS, Kim KH, Lee YJ, et al. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl 2007;13:741-746 DOI ScienceOn |
| 213 | Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661-1666 DOI ScienceOn |
| 214 | Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 2003;10:52-58 DOI ScienceOn |
| 215 | Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 2003;97:1253-1262 DOI ScienceOn |
| 216 | Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97 DOI ScienceOn |
| 217 | Park JW, An M, Choi JI,Kim YI, Kim SH, Lee WJ, et al. Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a Hepatitis B virusendemic area. J Cancer Res Clin Oncol 2007;133:937-943 DOI ScienceOn |
| 218 | Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-1440 DOI |
| 219 | Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996;111:720-726 DOI ScienceOn |
| 220 | Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403 DOI ScienceOn |
| 221 | You CR, Jang JW, Kang SH, Bae SH, Choi JY, Yoon SK, et al. Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis. Korean J Hepatol 2007;13:378-386 DOI ScienceOn |
| 222 | Zeng ZC, Tang ZY, Fan J, Qin LX, Ye SL, Zhou J, et al. Consideration of role of radiotherapy for lymphnode metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys 2005;63:1067-1076 DOI PUBMED ScienceOn |
| 223 | Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-165 PUBMED ScienceOn |
| 224 | Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomisedcontrolled trial comparing percutaneous radiofrequencythermal ablation, percutaneous ethanol injection, andpercutaneous acetic acid injection to treat hepatocellularcarcinoma of 3 cm or less. Gut 2005;54:1151-1156 DOI ScienceOn |
| 225 | O'Rourke N, Fielding G. Laparoscopic right hepatectomy: surgical technique. J Gastrointest Surg 2004;8:213-216 DOI ScienceOn |
| 226 | Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis 2007;25:313-319 DOI ScienceOn |
| 227 | Todo S, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-459 DOI ScienceOn |
| 228 | Volk M, Marrero JA. Liver transplantation for hepatocellularcarcinoma: who benefits and who is harmed?Gastroenterology 2008;134:1612-1614 DOI ScienceOn |
| 229 | Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, etal. Recurrence of hepatitis B is associated with cumulativecorticosteroid dose and chemotherapy againsthepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007;13:451-458 DOI ScienceOn |
| 230 | Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M,Takayama T, et al. Local recurrence of hepatocellularcarcinoma after percutaneous ethanol injection. Cancer 1996;77:1792-1796 DOI ScienceOn |
| 231 | Kaizu T, Karasawa K, Tanaka Y, Matuda T, Kurosaki H, Tanaka S, et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol 1998;93:2167-2171 DOI ScienceOn |
| 232 | Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-523 DOI ScienceOn |
| 233 | Ministry for Health, Welfare and Family Affairs, National Cancer Center. Annual report of cancer incidence (2005) and survival (1993-2005) in Korea. 2008 |
| 234 | Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003;37:1114-1121 DOI ScienceOn |
| 235 | Krinsky GA, Lee VS, Theise ND, Weinreb JC, Morgan GR, Diflo T, et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl 2002;8:1156-1164 DOI ScienceOn |
| 236 | Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y,et al. Percutaneous radiofrequency ablation for hepatocellularcarcinoma. An analysis of 1000 cases. Cancer 2005;103:1201-1209 DOI ScienceOn |
| 237 | Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 2002;24:395-403 DOI ScienceOn |
| 238 | Bae JH, Hong SW, Heo TG, Lee H. Characteristics and prognosis after resection for ruptured hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2006; 10:37-41 |
| 239 | Todo S, Furukawa H, Tada M; Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007;13(Suppl 2):S48-S54 DOI ScienceOn |
| 240 | Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150-159 DOI ScienceOn |
| 241 | Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H,Yoshikawa M, et al. Percutaneous ethanol injection forsmall hepatocellular carcinoma: therapeutic efficacy basedon 20-year observation. J Hepatol 2005;43:458-464 DOI ScienceOn |
| 242 | CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998;352:17-20 DOI PUBMED ScienceOn |
| 243 | Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK, Cho SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004;41:427-435 DOI ScienceOn |
| 244 | Agency for Healthcare Research Quality USPSTF. Ranking evidence about the effectiveness of treatments or screening |
| 245 | Matsui O. Detection and characterization of hepatocellular carcinoma by imaging. Clin Gastroenterol Hepatol 2005;3 (Suppl 2):S136-S140 DOI |
| 246 | Ferrero A, Vigano L, Polastri R. Ribero D, Lo Tesoriere R, Muratore, A, et al. Hepatectomy as treatment of choice for hepatocellular carcinoma in elderly cirrhotic patients. World J Surg 2005;29:1101-1105 DOI ScienceOn |
| 247 | Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, etal. Expansion of selection criteria for patients withhepatocellular carcinoma in living donor liver transplantation.Liver Transpl 2007;13:1637-1644 DOI ScienceOn |
| 248 | Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, SungKB, et al. Expanded indication criteria of living donorliver transplantation for hepatocellular carcinoma at onelarge-volume center. Liver Transpl 2008;14:935-945 DOI ScienceOn |
| 249 | Roberts JP. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2005;11(Suppl 2): S45-S46 DOI |
| 250 | Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430 DOI ScienceOn |
| 251 | Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005;11:1505-1514 DOI ScienceOn |
| 252 | Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and costeffectiveness perspective. Hepatology 2001;33:1073-1079 DOI ScienceOn |
| 253 | Lencioni RA, Allgaier HP, Cioni D, Olschewski M,Deibert P, Crocetti L, et al. Small hepatocellular carcinomain cirrhosis: randomized comparison of radiofrequencythermal ablation versus percutaneous ethanolinjection. Radiology 2003;228:235-240 DOI ScienceOn |
| 254 | Hsu HC, Chen TY, Chiu KW, Huang EY, Leung SW, Huang YJ, et al. Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma. Br J Radiol 2007;80:38-42 DOI PUBMED ScienceOn |
| 255 | Shah SA, Wei AC, Cleary SP, Yang I, McGilvray ID, Gallinger S, et al. Prognosis and results after resection of very large(>=10cm) hepatocelluar carcinoma. J Gastrointest Surg 2007;11:589-595 DOI ScienceOn |
| 256 | Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, et al. A randomized placebo-controlled study of longacting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-691 DOI ScienceOn |
| 257 | Horiike N, Iuchi H, Ninomiya T, Kawai K, Kumagi T, Michitaka K, et al. Influencing factors for recurrence of hepatocellular carcinoma treated with radiofrequency ablation. Oncol Rep 2002;9:1059-1062 PUBMED |
| 258 | Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-540 DOI ScienceOn |
| 259 | Park JW. National cancer screening program. Korean J Hepatol 2002;8(Suppl 3):S16-S19 |
| 260 | Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008;143: 469-475 DOI ScienceOn |
| 261 | Toso C, Meeberg GA, Bigam DL, Oberholzer J, ShapiroAM, Gutfreund K, et al. De novo sirolimus-basedimmunosuppression after liver transplantation for hepatocellularcarcinoma: long-term outcomes and side effects.Transplantation 2007;83:1162-1168 DOI ScienceOn |
| 262 | Buczkowski AK, Kim PT, Ho SG, Schaeffer DF, Lee SI, Owen DA, et al. Multidisciplinary management of ruptured hepatocellular carcinoma. J Gastrointest Surg 2006;10:379-386 DOI ScienceOn |
| 263 | Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007;141:330-339 DOI ScienceOn |
| 264 | Hwang S, Lee SG, Jung DH, Kim KH, Ha TY, Song GW. Simulation of deceased-donor liver graft allocation as UNOS status I or IIa on the current Korean setting for patients with hepatitis B virus-induced fulminant hepatic failure. Korean J Hepatobiliary Pancreat Surg 2009;13:31-36 |
| 265 | Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, HuRH, et al. Percutaneous ethanol injection versus surgicalresection for the treatment of small hepatocellularcarcinoma: a prospective study. Ann Surg 2005;242:36-42 DOI ScienceOn |
| 266 | Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16:205-213 DOI PUBMED ScienceOn |
| 267 | Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92 DOI ScienceOn |
| 268 | Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649 DOI ScienceOn |
| 269 | Marin D, Di Martino M, Guerrisi A, De Filippis G, Rossi M, Ginanni Corradini S, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 2009;251:85-95 DOI ScienceOn |
| 270 | Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Togo S. Intra-operative blood loss predicts complications after a second hepatectomy for malignant neoplasms. Ann Surg Oncol 2007;14:2668-2677 DOI ScienceOn |
| 271 | Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248:617-625 PUBMED ScienceOn |
| 272 | Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003;238:885-892 DOI ScienceOn |
| 273 | Miller C, Florman S, Kim-Schluger L, Lento P, De La Garza J, Wu J, et al. Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl 2004;10:1315-1319 DOI ScienceOn |
| 274 | Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008;15:1001-1007 DOI ScienceOn |
| 275 | Shirabe K, Kanematsu T, Matsumata T, AdachiE, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991;14:802-805 DOI PUBMED |
| 276 | Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L,Tinelli C, et al. Sustained complete response and complicationsrates after radiofrequency ablation of very earlyhepatocellular carcinoma in cirrhosis: is resection still thetreatment of choice? Hepatology 2008;47:82-89 DOI ScienceOn |
| 277 | Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT,et al. Randomized controlled trial of transarterial lipiodolchemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171 DOI ScienceOn |
| 278 | Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008;22:117-126 DOI ScienceOn |
 |
Korea Institute of Science and Technology Information
Gwahangno, Yuseong-gu, Daejeon, 305-806, Korea TEL : +82-42-869-1752
Copyright (c) 2009 KISTI. All Rights Reserved. For more information mail to
webmaster
